BERWYN, Pa.– AscellaHealth, a global healthcare and specialty pharmacy solutions company, announces its innovative life sciences solutions which address the challenges and barriers to accessing care and obtaining optimal outcomes that are facing rare disease patients – from burdensome social and financial difficulties, which may impede a timely start to therapy, to compliance issues relating to patients being able to stay on therapy. AscellaHealth’s unique solutions ensure that specialty products are successfully brought to market, while optimizing outcomes and the patient experience with a full spectrum of cutting-edge programs and services.
“Individuals with a rare disease or complex condition require a high level of support to ensure therapy adherence, as well as targeted programs and services that deliver specialized expertise that goes well beyond the traditional care continuum provided by legacy organizations that are simply built for scale,” says Dea Belazi, president and CEO, AscellaHealth. “AscellaHealth’s patient-first approach and high-level care coordination, highlight capabilities to strengthen communication and produce rich data for more informed decision-making that improves overall patient engagement to optimize outcomes. Our end-to-end solutions, including Hub and patient support services supporting life sciences, also empower clinical teams to seamlessly eliminate gaps in treatment.”
